The series seed financing round included investments from Hatteras Venture Partners, Point Judith Ventures, Common Angels, MassVentures, and Boston Global Ventures.
"For the last several years we have closely followed the market for bioinformatics platforms that address new challenges created by next-generation sequencing and biomedical big data," said Clay Thorp, general partner at Hatteras Venture Partners. "Curoverse has a clear strategy to use open source technology with a unique go-to-market model that is well-aligned with the needs of research and clinical customers."
Curoverse is available today through a private beta program. The company plans to release their first commercial products in 2014. The Arvados software is available at http://arvados.org.
Curoverse is a venture-backed startup developing computational storage infrastructure for a new era of precision medicine driven by genomic and biomedical big data. Based in Boston, Curoverse is a major contributor to the Arvados free and open source software project. Curoverse was formerly known as Clinical Future, Inc. More information is available about the company at http://curoverse.com.
Jonathan Sheffi, Curoverse
Read the full story at http://www.prweb.com/releases/2013/12/prweb11424292.htm.
Copyright©2012 Vocus, Inc.
All rights reserved